Related Experiment Videos
Dendritic cells in cancer immunotherapy.
1Departments of Pathology and Medicine, Stanford University School of Medicine, Palo Alto, California 94304, USA. lfong@stanford.edu
Annual Review of Immunology
|June 3, 2000
Summary
Cancer immunotherapy harnesses the immune system using dendritic cells (DCs) to present tumor antigens. These antigen-loaded DCs show promise in clinical trials for treating cancers like lymphoma and melanoma.
Area of Science:
- Immunology
- Oncology
- Cellular Biology
Background:
- Cancer immunotherapy leverages the immune system's potential for targeted tumor treatment.
- Dendritic cells (DCs), potent antigen-presenting cells derived from bone marrow, are key to generating tumor-specific immunity.
- Preclinical animal studies demonstrate that ex vivo antigen-loaded DCs can induce T cell-mediated tumor destruction in hosts.
Purpose of the Study:
- To investigate the immunologic and clinical effects of dendritic cell-based cancer vaccines.
- To explore the efficacy of using antigen-loaded DCs as a therapeutic vaccine for cancer patients.
Main Methods:
- Loading dendritic cells ex vivo with tumor-associated antigens.
- Administering antigen-loaded dendritic cells to tumor-bearing hosts.
- Considering critical factors like antigen selection, MHC processing pathways, DC isolation/activation, and administration route in clinical trial design.
Main Results:
- Clinical trials have been initiated to evaluate dendritic cell vaccination in cancer patients.
- Promising results observed in trials for malignant lymphoma, melanoma, and prostate cancer.
- Dendritic cell-based vaccines elicit T cell-mediated anti-tumor responses.
Conclusions:
- Dendritic cell-based immunotherapy holds significant potential for treating various human tumors.
- Despite current complexities, DC vaccination strategies show promise for broad applicability in oncology.
- Harnessing the antigen-presenting capabilities of DCs is a viable approach for cancer treatment.